Last updated: 2026-09-06 23:18:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BridgeBio Pharma, Inc. (BBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $74.83, with a market capitalization of $14.63B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $48.78 to $93.42. This page covers its latest market performance, valuation, price trends and company information.
$14.63B | |
$74.98 | |
$93.42 | |
$4.98 | |
$75.41 | |
1.27M | |
3.01M | |
-- | |
$93.42 | |
$48.78 | |
-- | |
-- |
BridgeBio Pharma, Inc. (BBIO) last closed at $75.41 as of 2026-09-04 23:31:00, unchanged from the previous close of $75.41.
During the latest regular trading session, BBIO traded between $4.98 and $93.42, with a volume of 1.27M shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, BridgeBio Pharma, Inc. (BBIO) moved from $78.68 to $74.83, representing a decline of 4.89% ($3.85).
The stock traded between $74.11 and $80.55 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.53 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 58.4%
BBIO is currently trading at $74.83, placing it 58.4% of the way from its 52-week low of $48.78 to its 52-week high of $93.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 839 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BridgeBio Pharma, Inc. (BBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.